Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emfilermin
- Development stage
- Phase 2
- Lead developer
- CSL
- Modality
- Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Emfilermin is a recombinant form of human leukemia inhibitory factor (LIF), a cytokine and growth factor involved in cell differentiation, proliferation, and survival. It was developed primarily for reproductive health indications, including improving embryo implantation following in vitro fertilization (IVF) and embryo transfer (ET) in women with recurrent implantation failure. Emfilermin has also been investigated for the prevention or amelioration of chemotherapy-induced peripheral neuropathy (CIPN). The drug acts as an agonist at the LIF receptor, stimulating downstream signaling pathways that support endometrial receptivity and potentially modulate neural protection. Despite promising preclinical rationale, clinical trials did not demonstrate significant efficacy for its intended indications[1][3][5][7].
- Other names
- leukemia inhibitory factor recombinant humanrecombinant human leukemia inhibitory factorLIF
02
Targets
LIFR (Leukemia inhibitory factor receptor)
Beyond the preview
Go deeper on emfilermin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emfilermin.